Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 363

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 363
---
 as Level 2 financial assets are recorded in Other assets on the consolidated balance sheets. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.

110

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)5. Fair Value of Financial Instruments (Continued)

Financial Assets and Liabilities Recorded at Fair Value on a Recurring BasisThe Company's financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands): Fair Value Measurements Total Fair Value at December 31, 2024Level 1Level 2Level 3Assets:Cash and cash equivalentsCash$37,830 $37,830 $— $— Money market funds31,501 31,501 — — Marketable securitiesCorporate debt securities355,201 — 355,201 — U.S government agency securities29,080 — 29,080 — Other noncurrent assetsMarketable securities - restricted (SERP)635 21 614 — Total assets at fair value$454,247 $69,352 $384,895 $— Liabilities:Contingent consideration$47,340 $— $— $47,340 Total liabilities at fair value$47,340 $— $— $47,340 

111

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)5. Fair Value of Financial Instruments (Continued)

 Fair Value Measurements Total Fair Value at December 31, 2023Level 1Level 2Level 3Assets:Cash and cash equivalentsCash$35,957 $35,957 $— $— Money market funds39,097 39,097 — — Marketable securitiesCorporate debt securities78,007 — 78,007 — Municipal debt securities10,916 — 10,916 — U.S. government agency debt securities90,897 — 90,897 — Long-term marketable securitiesCorporate debt securities16,617 — 16,617 — Other noncurrent assetsMarketable securities - restricted (SERP)568 16 552 — Total assets at fair value$272,059 $75,070 $196